BioNTech SE (Nasdaq:BNTX) will partner with Matinas BioPharma (NYSE AMER:MTNB) to develop mRNA formats that use Matinas’ proprietary lipid nanocrystal (LNC) platform technology that could enable oral delivery.
The two companies will partner on formulation, optimization and in vitro testing.
BioNTech CEO Dr. Ugur Sahin said that the partnership could lead to the development of mRNA-based vaccines that facilitate intracellular delivery and the potential for oral delivery.
“This collaboration with BioNTech is an important validation from a leading global biotech company with demonstrated expertise in the design, formulation and delivery of mRNA,” said Matinas CEO Jerome D. Jabbour.
BioNTech will pay Matinas an upfront exclusive access fee and provide additional research funding.
Filed Under: Drug Discovery and Development